News Headlines

  1. Ultragenyx Enters Into Strategic Partnership With Daiichi Sankyo For Gene Therapy Manufacturing Technology 3/31/2020

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, today announced a strategic partnership and non-exclusive license and technology access agreement with Daiichi Sankyo Company, Limited for Ultragenyx’s proprietary AAV-based gene therapy manufacturing technologies.

  2. Cobra Biologics Is Proud To Be Part Of A Consortium To Rapidly Develop A COVID-19 Vaccine 3/31/2020

    Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, today announced it is working as part of a consortium led by the Jenner Institute, Oxford University to rapidly develop, scale-up and produce the potential adenoviral vaccine candidate, ChAdOx1 nCov-19 (ChAdOx1), for fast-tracked clinical trials for COVID-19.

  3. CDMO Berkshire Sterile Manufacturing To Fill Initial COVID-19 Injectables For Clinical Trials 3/24/2020

    The Berkshires, known for its rich culture and charming green mountain towns has now become a manufacturer of novel treatments and medications to aid in the ongoing pandemic.

  4. Univercells Launches Cell & Gene Therapy Contract Development And Manufacturing Organization (CDMO) Exothera With GMP Capabilities In 15,000m2 Site In Jumet, Belgium 3/19/2020

    Univercells has launched a contract development and manufacturing organization (CDMO), Exothera, to support cell and gene therapy developers with process development and production of viral vectors.

  5. Coronavirus (COVID-19) Update: FDA Focuses On Safety Of Regulated Products While Scaling Back Domestic Inspections 3/18/2020

    Protecting the health and safety of our staff and their families is of paramount concern to the U.S. Food and Drug Administration. As a nation we must do everything we can to help slow the spread of the virus and help flatten the curve of the COVID-19 pandemic.

  6. Fujifilm Diosynth Biotechnologies To Invest $83M To Expand Microbial Manufacturing Capacity 3/18/2020

    FUJIFILM Corporation announced today that it will invest approximately 9 billion yen ($83M USD) to expand the microbial production capacity of FUJIFILM Diosynth Biotechnologies (FDB), a world leading cGMP Contract Development & Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and production of their biologics, vaccines and gene therapies.

  7. Roivant Announces Development Of Anti-GM-CSF Monoclonal Antibody To Prevent And Treat Acute Respiratory Distress Syndrome (ARDS) In Patients With COVID-19 3/18/2020

    Roivant Sciences today announced that it has engaged with regulators in the United States, Europe, and Asia to rapidly advance the clinical development of gimsilumab for the treatment of acute respiratory distress syndrome (ARDS) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

  8. Bora's responsibility To navigate COVID-19 3/16/2020

    As the world is fighting to contain the COVID-19 (the coronavirus), I wanted to reach out and provide an update on the actions that Bora is taking to prevent the spread of the virus, ensure business continuity, and support the health and well-being of our customers, employees and communities.

  9. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization To Thermo Fisher 3/13/2020

    Today, the U.S. Food and Drug Administration took another significant diagnostic action during the coronavirus outbreak (COVID-19)

  10. FUJIFILM Diosynth Biotechnologies Breaks Ground On A New Biocampus At Its Billingham, UK Location 3/12/2020

    FUJIFILM Diosynth Biotechnologies (FDB), a world leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and production of their biologics, vaccines and gene therapies, held a ground breaking ceremony on March 10, 2020 signalling commencement of construction of the company’s new BioCampus at its Billingham, UK location.